

Working with the pharmaceutical industry

Leukaemia Care works closely with the pharmaceutical industry to make sure the voices and needs of people affected by blood cancers are heard when new drugs and treatments are developed. We also receive funding from pharmaceutical companies under clear guidelines to maintain independence and transparency.

Why we work with the pharmaceutical industry

Collaborative work with pharmaceutical companies helps ensure that patient views are taken into account during the development and marketing of new drugs and treatments for blood cancer patients. This includes advising companies, alone or with other charities, so that people's lived experiences inform decisions about therapies that may affect their lives.

We also receive funding from a range of pharmaceutical companies. All funding is handled and used in accordance with the [ABPI Code of Practice](#) and Leukaemia Care's own Code of Practice. This approach is designed to minimise any real or perceived conflict of interest while allowing us to continue our vital work supporting patients and families.

Independence and transparency

Leukaemia Care values its independence and is committed to avoiding any undue influence from external partners, including pharmaceutical companies. We will not promote or endorse individual products or services. If a company attempts to influence our decisions on marketing or content, we will refuse support or end the partnership.

In order to properly maintain independence and remain compliant, we place strict rules on the amount of funding we receive from the pharmaceutical industry. We will never accept an amount of money from an individual company that equates to

<https://lcdemo-stage.gb.aldryn.io/get-involved/fundraise-for-leukaemia-care/corporate-partnerships/working-with-the-pharmaceutical-industry/>

Leukaemia Care Registered Charity Number 1183890. Scotland Registered Charity Number SC049802

Helpline: [08088 010 444](tel:08088010444)

more than 10% of our annual income and have a limit of 25% of our total budget from the industry as a whole.

We also believe in being open about the funding we receive. In the 2024 financial year, we received £ 168,200 from pharmaceutical companies. Details can be found in our annual report.

Working with others

Our patient advisory work on medicines and treatments often happens in collaboration with other patient groups and charities. By working together, we can better represent the collective needs of people with blood cancer and help shape decisions that affect treatment and care.